Selective phosphodiesterase-3 inhibitor cilostazol ameliorates experimental autoimmune encephalomyelitis

NeuroReport

Volumn 20, Issue 7, 2009, Pages 718-722

  Kureshiro, Juri ^a   Miyamoto, Katsuichi ^a   Tanaka, Noriko ^a   Kusunoki, Susumu ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adhesion molecules; Cilostazol; Experimental autoimmune encephalomyelitis; Intercellular adhesion molecule 1; Multiple sclerosis; P selectin; Phosphodiesterases inhibitor

Indexed keywords

CILOSTAZOL; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; PEPTIDE DERIVATIVE; PHOSPHODIESTERASE III INHIBITOR; GLYCOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35 55); MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); PADGEM PROTEIN; PEPTIDE FRAGMENT; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; TETRAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; IMMUNE RESPONSE; IMMUNOREGULATION; INOCULATION; LYMPHOCYTE PROLIFERATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCORING SYSTEM; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; HOSPITALIZATION; LYMPH NODE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GLYCOPROTEINS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-17; LYMPH NODES; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; P-SELECTIN; PEPTIDE FRAGMENTS; PHOSPHODIESTERASE INHIBITORS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TETRAZOLES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 67049113770     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e32832aa990     Document Type: Article

References (21)

1. Lugnier R. Cyclic nucleotide phosphodiesterase superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006; 109:366-398.
2. Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kurabayashi M, et al. Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-κB binding to its recognition sequence. Atherosclerosis 2001; 158:121-128.
3. Kim KY, Shin HK, Choi JM, Hong KW. Inhibition of lipopolysaccharide- induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 2002; 300:709-715.
4. Nishio Y, Kashiwagi N,Takahara N, Hidaka H, Kikkawa R. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-α in vascular endothelial cells. Hrm Metab Res 1997; 29:491-495.
5. Tamaru T, Suzumura A, Takayanagi T. Inhibitory effects of phosphodiesterase inhibitors on experimental autoimmune encephalomyelitis. Neuroimmunology 1998; 6:154-155.
6. Fujimoto T, Sakoda S, Fujimura H, Yanagihara T. Ibudilast, a phospho- diesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol 1999; 95:35-42.
7. Dinter H, Tse J, Halks-Miller M, Asarnow D, Onuffer J, Faulds D, et al.The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J Neuroimmunol 2000; 108:136-146.
8. Martine I, Puerta C, Redondo C, Garcia-Merino A. Type IV phosphodiesterase inhibition in experimental allergic encephalomyelitis of Lewis rats: sequential gene expression analysis of cytokines, adhesion molecules and the inducible nitric oxide synthase. J Neurol Sci 1999; 164:13-23.
9. Moore CS, Earl N, Frenette R, Styhler A, Mancini JA, Nicholson DW, et al. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bisdifluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2- hydroxypropan-2-yl)- phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 2006; 319:63-72.
10. Miyamoto K, Miyake S, Mizuno M, Oka N, Kusunoki S, Yamamura T. Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain 2006; 129:1984-1992.
11. Claveau D, Chen SL, O'Keefe S, Zaller DM, Styhler A, Liu S, et al. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-2-(3,4-Bisdifluromethoxyphenyl)-2-4-(1,1,1,3,3, 3-hexafluoro-2-hydroxypropan-2-yl)-phenyl-ethyl-3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 2004; 310:752-760.
12. Suzumura A, Ito A, Yoshikawa M, Sawada M. Ibudilast suppresses TNFα production by Glias cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res 1999; 837:203-212.
13. Suzumura A, Ito A, Mizuno T. Phosphodiesterase inhibitors suppress IL-12 production with Microglia and T helper 1 development. Mult Scler 2003; 9:574-578.
14. Bielekova B, Lincoln A, Mcfarland H, Martin R. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 2000; 164:1117-1124.
15. Yoshikawa M, Suzumura A, Tamaru T, Takayanagi T, Sawada M. Effects of phosphodiesterase inhibitors on cytokine production by microglia. Mul Scler 1999; 5:126-133.
16. Bullard DC, Hu X, Schoeb TR, Collins RG, Beardet AL, Barnum SR. Intercellular adhesion molecule-1 expression is required on multiple cell type for the development of experimental autoimmune encephalomyelitis. J Immunol 2007; 178:851-857.
17. Dore-Duffy P, Washington R, Dragovic L. Expression of endothelial cell activation antigens in microvessels from patients with multiple sclerosis. Adv Exp Med Biol 1993; 331:243-248.
18. Sharief MK, Noori MA, Ciardi M, Cirelli A, Thompson EJ. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage. J Neuroimmunol 1993; 43:15-21.
19. Rieckmann P, Nunke K, Burchhardt M, Albrecht M, Wiltfang J, Ulrich M, et al. Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier. J Neuroimmunol 1993; 47:133-140.
20. Nomura S, Shouzu A, Omoto S, Hayakawa T, Kagawa H, Nishikawa M, et al. Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb Haemost 1998; 80:388-392.
21. Omi H, Okayama N, Shimizu M, Fukutomi T, Nakamura A, Imaeda K, et al. Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production. Microvasc Res 2004; 68:119-125.